Bolt biotherapeutics to present data from phase 1 dose-escalation clinical study of bdc-3042 at aacr annual meeting 2025

Redwood city, calif., march 25, 2025 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the phase 1 dose-escalation clinical study of bdc-3042 in patients with advanced cancers at the american association for cancer research (aacr) annual meeting, taking place april 25-30, 2025, in chicago, illinois.
BDC Ratings Summary
BDC Quant Ranking